Neuron23

The primary endpoint of our Phase 2 NEULARK clinical trial of NEU-411 incorporates a digital biomarker and smartphone-based solution developed by Roche Information Solutions (RIS), the Roche group focused on digital health solutions. Clinical development in #Parkinsons disease (PD) has historically been challenged by symptom variability that reduces the sensitivity and reliability of clinical outcome assessments. Potential benefits of the navify? digital biomarker solution include significantly greater frequency of data measurement and more objective and precise quantification of symptoms. Learn more about Neuron23’s usage of Roche’s digital biomarker and device in our PD clinical trial here: https://lnkd.in/gUTJXeB8

We're excited to share details about our Phase 2 NEULARK trial of NEU-411, a brain-penetrant, potent and selective inhibitor of #LRRK2, in people living with early #Parkinsons disease (PD). The NEULARK trial represents a significant #precisionmedicine advancement in how we can effectively identify and measure therapeutic impact in LRRK2-driven PD, estimated to affect up to 30% of people living with the disease. Listen in as Chief Medical Officer Sam Jackson, EVP of Drug Discovery Steve Wood, and Executive Director of Clinical and Digital Development Fatta B. Nahab MD, FAAN, FANA, discuss the importance of NEU-411 and how this innovative trial in PD differentiates itself. Our LRRK2 program is a key driver of innovation within our neuroimmunology pipeline, and we are on track to initiate this trial early in 2025. Read more here: https://lnkd.in/eShmssCC

The foundation of innovation is rooted in a dynamic, motivated, and well-educated workforce proficient in #STEM skills. In honor of #NationalSTEMDay, our team members shared some of their experiences in STEM to inspire the next generation to explore the exciting possibilities within this field. Check out responses from Anh Truong, Nathan Peterson, and David T. below!

Happy #Halloween from Neuron23! We celebrated the fall season with a costume party at the office. There's no better way to keep the team close than enjoying each other's company over good food and drinks. Check us out below and tell us which costume is your favorite.

Our Chief Medical Officer, Sam Jackson, and EVP of Drug Discovery, Steve Wood, had the honor of attending the 2024 Parkinson’s Disease Therapeutics Conference hosted by The Michael J. Fox Foundation for Parkinson's Research. This event provided invaluable insights into the latest advancements in research and treatments, fostering connections that will help drive innovation in therapeutics strategies for #Parkinsons patients.

It’s always a pleasure having the opportunity to partner with Samaritan House of San Mateo County for various #volunteer efforts throughout the year. Our team got together to pack backpacks full of supplies to help students start the year strong, and we also lent a hand with the regular food distribution to help families in need. We’re proud to come together and do our part, offering support and hope to those who need it most. By joining hands, we’re making a difference and driving our mission to enhance and improve the lives of those around us.

We recently hosted our board member, Kathy Dong, PharmD, MBA, at our office for a fireside chat. She shared her background as a leader within the #biotech industry and some of the challenges she faced along the way. Thank you, Dr. Dong, for sharing your experiences and expertise, and for playing a key role in helping us achieve our mission of combatting debilitating neurological and immunological diseases.

Our Director, in vivo Pharmacology Tyler Molitor, Ph.D. will be presenting a poster at the 40th Congress of the ECTRIMS. Tyler will showcase how the TYK2 enzyme plays an important role in regulating immune responses in the central nervous system and its implications for understanding and treating #neuroinflammatory diseases. Learn more about #ECTRIMS2024 here:?https://lnkd.in/d65mHk38?

Please join us in welcoming Taylor P., Clinical Trial Manager?at Neuron23. We're so excited to have you on board, Taylor! #NewHires #Neuron23

Please join us in welcoming Thomas DeMelfi, Vice President, Regulatory Affairs and Quality?at Neuron23. We're so excited to have you on board, Thomas! #NewHires #Neuron23